{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"249"}],"units":"Participants"}],"title":"C1D1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"212"}],"units":"Participants"}],"title":"C2D2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"159"}],"units":"Participants"}],"title":"C5D1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"}],"units":"Participants"}],"title":"C9D1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"title":"C13D1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"title":"C17D1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"}],"units":"Participants"}],"title":"30 Day follow up"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"title":"90 Day follow up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"249"}],"units":"Participants"}],"description":"Immunogenicity will be measured by the number of participants that are ADA positive.","groups":[{"description":"Participants received an intravenous (IV) infusion (as a minimum of 2-hour infusion) of zolbetuximab at a loading dose of 800 milligrams per square meter (mg/m\\^2) on cycle 1 day 1 (C1D1) followed by subsequent doses of 600 mg/m\\^2 every 3 weeks starting from C2D1 until participant met study treatment discontinuation criteria. Participants also received up to 8 treatments of capecitabine and oxaliplatin (CAPOX) treatment. Oxaliplatin was administered 130 mg/m\\^2 IV on day 1 of each cycle over 2 hours for a maximum of 8 treatments; Capecitabine was administered orally at 1000 mg/m\\^2 twice daily (bid) on days 1 through 14 of each cycle until the participant met study treatment discontinuation criteria. After a maximum of 8 treatments of oxaliplatin, participants may have continued to receive capecitabine taken twice daily on days 1 through 14 of each cycle at the investigator's discretion until the participant met study treatment discontinuation criteria. Each cycle was approximately 21","id":"OG000","title":"CAPOX+ Zolbetuximab"}],"paramType":"NUMBER","populationDescription":"Participants who were Randomized to Zolbetuximab + CAPOX Arm with at least One Valid Result for ADA","reportingStatus":"POSTED","timeFrame":"Predose on C1D1,C2D1,C5D1,C9D1,C13D1,C17D1, 30-day follow up, 90-day Follow up","title":"Number of Anti-drug Antibody (ADA) Positive Participants","type":"SECONDARY","unitOfMeasure":"Participants"}